Seattle Genetics Diversifies Beyond ADCs With Cascadian Acquisition

The biotech already was looking to move into solid tumors, particularly breast cancer, with its antibody-drug conjugates, but now will take over a promising oral candidate in pivotal studies in HER2-positive breast cancer.